Overall, in KEAP1 mutant NSCLC, NRF2 does not fully control the FSP1, indicating that inhibiting NRF2 alone does not overcome RSL3-induced ferroptosis resistance. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.